Q-omics provides the consensus-scored RPLP0P7 profile across patient tissues and cancer cell-line models. RPLP0P7 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RPLP0P7 is differentially expressed in 3, with the highest sampling consensus in COAD. Additionally, RPLP0P7 RNA expression shows 3,806 significant pathway-activity associations, with the highest sampling consensus in LUSC. Together, these results highlight KIRP, COAD, and LUSC as cancer lineages where RPLP0P7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPLP0P7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPLP0P7 survival associations across molecular data types. RPLP0P7 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPLP0P7 RNA expression–survival associations across cancer types. High RPLP0P7 expression shows unfavorable associations in KIRP, THYM, ACC, MESO and BRCA, but favorable associations in BLCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RPLP0P7 RNA expression.
This table summarizes RPLP0P7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPLP0P7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPLP0P7 shows lower tumor expression in ESCA and higher tumor expression in COAD and LUAD. The COAD box plot shows higher RPLP0P7 RNA expression in tumor versus normal tissue (log2 FC = +0.136, t-test p = .012).
This table shows molecular features associated with RPLP0P7 in patient tissues and cancer cell lines. In patient samples, RPLP0P7 shows the broadest associations at the RNA and protein expression levels, with LUSC recurring as the lineage with the largest associated feature set.
